NeuroSense Therapeutics Ltd. (NRSNW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Les analystes estiment Bénéfice par action (EPS) de $-0.65 et chiffre d'affaires de $0.00B pour le prochain exercice fiscal.
Historique du Bénéfice par action (EPS): 2024: réel $-0.55 vs est $-0.65 (dépassé +15.4%). Précision des analystes: 82%.
